FDA Approval for Sanofi Drug Marks an Important First in Rare Disease
Sanofi’s Infilbray is now approved for treating Gaucher disease type 3. The brain-penetrating small molecule is the first FDA-approved therapy for the neurological symptoms of this rare enzyme deficiency.